Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Immunovant, Inc.

IMVT · Nasdaq · CIK 0001764013 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

54 Form 4 transaction lines observed in the same window
39 sales · 15 option, withholding, award, gift or other lines

Last qualifying purchase2025-12-12 · Roivant Sciences Ltd. · $350.0M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesHigh
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Pande AtulDirector
○▼○▼○▼○▼○▼
Van Tuyl ChristopherChief Legal Officer
▼○▼▼▼▼
Venker EricChief Executive Officer
○○▼○○▼
Stout Jay SChief Technology Officer
▼▼▼▼▼
Gloria MelanieChief Operating Officer
▼▼▼▼▼
Girao TiagoChief Financial Officer
▼○▼▼
● Purchase▼ Sale○ Other

Showing the six most active owners; 2 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-12-12 · Roivant Sciences Ltd..

Recent Form 4 activity

1Purchases
62Sales
28Other Form 4 lines
53SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING39 sale line(s) · context only
OTHER15 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
17,416,613
Previous report
17,253,948
Avg daily volume
1,805,887
Days to cover
9.6

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-12-12Roivant Sciences Ltd.Purchase (P)Common Stock, $0.0001 par value per share16,666,666USD 21.00USD 349,999,986SEC filing ↗
2025-01-13Roivant Sciences Ltd.Purchase (P)Common Stock, $0.0001 par value per share16,845,010USD 20.00USD 336,900,200SEC filing ↗
2023-10-02Roivant Sciences Ltd.Purchase (P)Common Stock, $0.0001 par value per share1,526,316USD 38.00USD 58,000,008SEC filing ↗
2022-10-06Roivant Sciences Ltd.Purchase (P)Common Stock, $0.0001 par value per share416,667USD 6.00USD 2,500,002SEC filing ↗
2022-09-30Pande AtulPurchase (P)Common Stock15,000USD 5.60USD 84,000SEC filing ↗
2022-09-29Torti FrankPurchase (P)Common Stock20,000USD 5.81USD 116,200SEC filing ↗
2021-08-27Hughes Douglas J.Purchase (P)Common Stock18,247USD 8.24USD 150,355SEC filing ↗
2021-08-20MIGAUSKY GEORGE VPurchase (P)Common Stock7,000USD 7.65USD 53,550SEC filing ↗
2021-08-13Pande AtulPurchase (P)Common Stock5,000USD 7.98USD 39,900SEC filing ↗
2021-08-10Fromkin Andrew J.Purchase (P)Common Stock5,500USD 7.90USD 43,450SEC filing ↗
2020-09-11Butchko Julia G.Purchase (P)Common Stock5,000USD 38.17USD 190,850SEC filing ↗
2020-09-04Roivant Sciences Ltd.Purchase (P)Common Stock, $0.0001 par value per share380,000USD 33.00USD 12,540,000SEC filing ↗
2020-04-16Roivant Sciences Ltd.Purchase (P)Common Stock, $0.0001 par value per share1,034,483USD 14.50USD 15,000,004SEC filing ↗

Form 4 evidence

91 transaction lines in the latest 365-day window; 382 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-07Van Tuyl ChristopherSale (S)Common Stock1,327USD 32.06USD 42,544SEC filing ↗
2026-10-07Stout Jay SSale (S)Common Stock3,809USD 32.06USD 122,117SEC filing ↗
2026-10-07Gloria MelanieSale (S)Common Stock2,241USD 32.06USD 71,846SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-07Van Tuyl ChristopherSale (S)Common Stock1,327USD 32.06USD 42,544SEC filing ↗
2026-10-07Stout Jay SSale (S)Common Stock3,809USD 32.06USD 122,117SEC filing ↗
2026-10-07Gloria MelanieSale (S)Common Stock2,241USD 32.06USD 71,846SEC filing ↗
2026-10-02Venker EricSale (S)Common Stock3,506USD 34.11USD 119,590SEC filing ↗
2026-10-01Venker EricOption exercise / conversion (M)Common Stock92,187USD 14.46USD 1,333,024SEC filing ↗
2026-10-01Venker EricD (D)Common Stock85,886USD 33.65USD 2,890,064SEC filing ↗
2026-09-23Van Tuyl ChristopherSale (S)Common Stock2,846USD 36.36USD 103,481SEC filing ↗
2026-08-28Pande AtulSale (S)Common Stock1,500USD 43.27USD 64,905SEC filing ↗
2026-08-28Pande AtulOption exercise / conversion (M)Common Stock1,500USD 8.43USD 12,645SEC filing ↗
2026-08-20Gloria MelanieSale (S)Common Stock3,056USD 44.16USD 134,953SEC filing ↗
2026-07-24Pande AtulSale (S)Common Stock1,500USD 39.80USD 59,700SEC filing ↗
2026-07-24Pande AtulOption exercise / conversion (M)Common Stock1,500USD 8.43USD 12,645SEC filing ↗
2026-07-23Stout Jay SSale (S)Common Stock2,857USD 38.69USD 110,537SEC filing ↗
2026-07-23Girao TiagoSale (S)Common Stock6,798USD 38.69USD 263,015SEC filing ↗
2026-07-08Van Tuyl ChristopherSale (S)Common Stock1,206USD 39.55USD 47,702SEC filing ↗
2026-07-08Stout Jay SSale (S)Common Stock3,487USD 39.55USD 137,925SEC filing ↗
2026-07-08Gloria MelanieSale (S)Common Stock2,036USD 39.55USD 80,532SEC filing ↗
2026-07-02Venker EricSale (S)Common Stock3,092USD 38.48USD 118,980SEC filing ↗
2026-07-01Venker EricOption exercise / conversion (M)Common Stock92,188USD 14.46USD 1,333,038SEC filing ↗
2026-07-01Venker EricD (D)Common Stock86,629USD 38.14USD 3,304,030SEC filing ↗
2026-06-26Van Tuyl ChristopherSale (S)Common Stock17,824USD 38.31USD 682,887SEC filing ↗
2026-06-26Van Tuyl ChristopherOption exercise / conversion (M)Common Stock17,824USD 15.20USD 270,925SEC filing ↗
2026-06-26Stout Jay SSale (S)Common Stock40,000USD 38.31USD 1,532,309SEC filing ↗
2026-06-26Pande AtulSale (S)Common Stock1,500USD 38.01USD 57,015SEC filing ↗
2026-06-26Pande AtulOption exercise / conversion (M)Common Stock1,500USD 8.43USD 12,645SEC filing ↗
2026-06-26Gloria MelanieSale (S)Common Stock17,714USD 38.31USD 678,604SEC filing ↗
2026-06-26Girao TiagoSale (S)Common Stock10,000USD 38.46USD 384,600SEC filing ↗
2026-06-26Girao TiagoOption exercise / conversion (M)Common Stock10,000USD 15.90USD 159,000SEC filing ↗
2026-06-18Van Tuyl ChristopherSale (S)Common Stock2,634USD 35.39USD 93,217SEC filing ↗
2026-06-15Pande AtulSale (S)Common Stock1,500USD 34.02USD 51,030SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerIMVT
CIK0001764013
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history382 transaction lines from 2020-04-16 to 2026-10-07
13 P purchase lines · 257 S sale lines · 112 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.